Agios Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04015687
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03991312
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03960502
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03853798
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Indiana Hemophilia & Thrombosis Center Inc., Indianapolis, Indiana, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03834584
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03703505
- Locations
- 🇺🇸
Covance, Madison, Wisconsin, United States
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03692052
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇨🇦University Health Network (Toronto General Hospital), Toronto, Ontario, Canada
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03559699
- Locations
- 🇬🇧
University College London, London, United Kingdom
🇹🇭Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03548220
- Locations
- 🇬🇧
The Royal Liverpool and Broadgreen University, Liverpool, United Kingdom
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Pyruvate Kinase Deficiency Global Longitudinal Registry
- Conditions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT03481738
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States